TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report)’s stock price fell 4.5% on Thursday . The company traded as low as $3.80 and last traded at $3.84. 361,715 shares changed hands during trading, a decline of 90% from the average session volume of 3,511,287 shares. The stock had previously closed at $4.02.
TNF Pharmaceuticals Stock Up 2.1%
The firm has a market cap of $7.11 million, a P/E ratio of -0.02 and a beta of 2.04. The business’s 50 day moving average is $4.15 and its two-hundred day moving average is $4.26.
TNF Pharmaceuticals Company Profile
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.
Featured Stories
- Five stocks we like better than TNF Pharmaceuticals
- Silver paying 20% dividend. Plus 68% share gains
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- Iran isn’t the real war
- How JPMorgan’s $8,000 Gold Call Will Leave Most Retirement Accounts Behind
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
